Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model

被引:7
作者
de Diego, R. Perez [1 ,2 ]
Lopez-Granados, E. [2 ]
Rivera, J. [1 ]
Ferreira, A. [2 ]
Fontan, G. [2 ]
Bravo, J. [1 ]
Rodriguez, M. C. Garcia [2 ]
Bolland, S. [3 ]
机构
[1] Spanish Natl Canc Res Ctr CNIO, Signal Transduct Grp, Madrid 28029, Spain
[2] Univ Hosp La Paz, Immunol Unit, Madrid, Spain
[3] NIAID, NIH, Rockville, MD USA
关键词
Bruton's tyrosine kinase; calcium mobilization; DT40; cells; gene therapy; X-linked agammaglobulinaemia;
D O I
10.1111/j.1365-2249.2008.03589.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
X-linked agammaglobulinaemia (XLA) is characterized by absence of mature B cells because of mutations in the Bruton's tyrosine kinase (Btk) gene. Btk-deficient early B cell precursors experience a block in their differentiation potentially reversible by the addition of an intact Btk gene. Btk expression was measured in 69 XLA patients with 47 different mutations and normal expression was detected in seven. We characterized these Btk mutant forms functionally by transfection into a lymphoma cell line that lacks endogenous Btk expression (Btk(-/-) DT40 cells) and analysed the calcium flux in response to B cell receptor stimulation. To test whether co-expression of a mutated form could compromise the function of the intact Btk transfection, studies in wild-type (WT) DT40 cells were also performed. Study reveals that none of the seven Btk mutants analysed was able to revert the absence of calcium mobilization upon IgM engagement in Btk(-/-) DT40 cells, as does intact Btk. In addition, calcium mobilization by anti-IgM stimulation in DT40 Btk(+/+) cells was unaffected by co-expression with Btk mutants. These results suggest that gene addition would be feasible not only for patients with XLA and mutations that prevent Btk expression, but for those with expression of a mutant Btk.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 38 条
[1]   Diagnostic guidelines - An international consensus document [J].
Conley, ME .
CLINICAL IMMUNOLOGY, 1999, 93 (03) :189-189
[2]   Genetic analysis of patients with defects in early B-cell development [J].
Conley, ME ;
Broides, A ;
Hernandez-Trujillo, V ;
Howard, V ;
Kanegane, H ;
Miyawaki, T ;
Shurtleff, SA .
IMMUNOLOGICAL REVIEWS, 2005, 203 :216-234
[3]   DEFINITION OF THE GENE LOCI IN X-LINKED IMMUNODEFICIENCIES [J].
CONLEY, ME ;
PUCK, JM .
IMMUNOLOGICAL INVESTIGATIONS, 1988, 17 (05) :425-463
[4]   Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes [J].
de Diego, Rebeca Perez ;
Lopez-Granados, Eduardo ;
Pozo, Maite ;
Rodriguez, Cristina ;
Sabina, Prado ;
Ferreira, Antonio ;
Fontan, Gurnersindo ;
Garcia-Rodriguez, Maria Cruz ;
Alemany, Susana .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (06) :1462-1469
[5]   Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells [J].
Feldhahn, N ;
Rio, P ;
Soh, BNB ;
Liedtke, S ;
Sprangers, M ;
Klein, F ;
Wernet, P ;
Jumaa, H ;
Hofmann, WK ;
Hanenberg, H ;
Rowley, JD ;
Müschen, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (37) :13266-13271
[6]   Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity [J].
Fukuda, M ;
Kojima, T ;
Kabayama, H ;
Mikoshiba, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (48) :30303-30306
[7]  
Futatani T, 1998, BLOOD, V91, P595
[8]   Early B cell defects [J].
Gaspar, HB ;
Conley, ME .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 119 (03) :383-389
[9]   Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor at production [J].
Horwood, NJ ;
Mahon, T ;
McDaid, JP ;
Campbell, J ;
Mano, H ;
Brennan, FM ;
Webster, D ;
Foxwell, BMJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (12) :1603-1611
[10]  
Kurosaki T, 2000, IMMUNOL REV, V176, P19